Codis将收购 Catalent位于英国诺丁汉的工厂，以打造欧洲领先的端到端喷雾干燥能力-动脉网

Codis To Acquire Catalent's Nottingham, UK Facility to Create Europe's Leading End-to-End Spray Dry Capability

PR Newswire 等信源发布 2026-07-06 20:57



可切换为仅中文







With this acquisition, Codis becomes a leading provider of end-to-end spray dry solutions in Europe

通过此次收购，Codis 成为欧洲领先的端到端喷雾干燥解决方案提供商。

Nottingham adds oral solid dose development and small-scale commercial manufacturing with over two decades of expertise in the UK

诺丁汉凭借在英国二十余年的专业经验，新增口服固体制剂开发和小规模商业化生产能力

The acquisition strengthens Codis' particle engineering expertise and complements the commercial-scale GEA PSD-4 investment in Haverhill, UK

此次收购增强了Codis在颗粒工程领域的专业能力，并与其在英国哈弗希尔对GEA PSD-4的商业化规模投资形成互补。

HAVERHILL, England

英格兰哈弗希尔

，

July 6, 2026

2026年7月6日

/PRNewswire/ -- Codis, a global contract development and manufacturing organization (CDMO) specializing in spray drying, amorphous solid dispersions (ASDs), and advanced particle engineering solutions, today announced an agreement with Catalent Pharma Solutions ('Catalent') to acquire Catalent's facility in Nottingham, UK.

/美通社/ -- 专注于喷雾干燥、无定形固体分散体（ASDs）和先进颗粒工程解决方案的全球合同研发与生产组织（CDMO）Codis，今日宣布与康泰伦特医药解决方案公司（Catalent Pharma Solutions，简称“Catalent”）达成协议，收购其在英国诺丁汉的工厂。

The acquisition, expected to close in Q3 of this year subject to customary closing conditions, will add oral solid dose (OSD) development and small-scale manufacturing capabilities and create Europe's leading single partner path for integrated spray dry solutions, from development through clinical supply and commercial intermediates, to final oral dose forms..

此次收购预计将在今年第三季度完成，前提是满足惯例性的交割条件。该交易将增加口服固体制剂（OSD）的开发和小规模生产能力，并打造欧洲领先的单一合作伙伴路径，提供从开发到临床供应及商业中间体，直至最终口服剂型的集成喷雾干燥解决方案。

The Nottingham site brings a highly experienced team and deep scientific expertise in formulation development and clinical supply, successfully delivering development-scale spray drying and OSD solutions for over two decades. Codis is excited to welcome the Nottingham team into the organization.

诺丁汉基地拥有一支经验丰富的团队，在制剂开发和临床供应方面具备深厚的科学专业知识，二十多年来成功提供了开发规模的喷雾干燥和口服固体制剂（OSD）解决方案。Codis 对诺丁汉团队加入公司表示热烈欢迎。

This acquisition will strategically complement Codis' large scale commercial spray drying facility in Haverhill, UK, which is now undergoing significant expansion with a new GEA Pharma-SD® type PSD-4 commercial spray dryer scheduled to be validated in 2027. It will also augment Codis' current portfolio of bioavailability enhancement solutions with integrated development, analytical, and clinical and small-scale commercial manufacturing co-located at the site..

此次收购将在战略上补充Codis位于英国哈夫希尔的大规模商业喷雾干燥设施，该设施目前正在大幅扩建中，计划于2027年验证一台全新的GEA Pharma-SD®型PSD-4商业喷雾干燥机。此外，此次收购还将增强Codis现有的生物利用度提升解决方案组合，其整合的开发、分析以及临床和小规模商业化制造能力均集中于同一场地。

'This strategic acquisition will further establish Codis as a leading European provider of comprehensive spray dry solutions,' said Nicolas Fortin, CEO of Codis. 'The close proximity of our Nottingham and Haverhill sites creates a unique advantage. Codis can now offer access to the best scientific expertise with a strong, integrated manufacturing capability within a single organization and quality system.'.

Codis 首席执行官 Nicolas Fortin 表示：“此次战略性收购将进一步巩固 Codis 作为欧洲领先的全面喷雾干燥解决方案提供商的地位。我们位于诺丁汉和哈弗希尔的站点地理位置邻近，形成了独特的优势。Codis 现在能够在单一组织和质量体系内，提供顶尖的科学专业知识以及强大的集成化制造能力。”

Mr Fortin noted, 'Most small-molecule drug candidates suffer from poor solubility, and spray-dried dispersions have become one of the primary approaches to improving bioavailability. Yet one of the greatest development risks remains the transfer from formulation to commercial-scale manufacturing. By bringing formulation development and GMP manufacturing together, we provide the fastest, lowest-risk path to unlocking a molecule's full potential.'.

Fortin先生指出：“大多数小分子药物候选物存在溶解度差的问题，而喷雾干燥分散体已成为提高生物利用度的主要方法之一。然而，从制剂开发到商业化规模生产的转移仍然是最大的开发风险之一。通过将制剂开发与GMP生产相结合，我们提供了释放分子全部潜力的最快、最低风险路径。”

About Codis

关于 Codis

Codis is a global CDMO specializing in commercial spray drying, amorphous solid dispersions, particle engineering, and finished dose manufacturing for the pharmaceutical, consumer health, nutraceutical, and OTC sectors. With more than 400,000 sq ft of cGMP facilities in St. Louis, Missouri, Seymour, Indiana, and Haverhill, UK, Codis combines decades of regulatory expertise, development and manufacturing strength under one brand.

Codis 是一家全球性合同研发生产组织（CDMO），专注于为制药、消费者健康、营养保健品和非处方药（OTC）领域提供商业化喷雾干燥、无定形固体分散体、粒子工程和成品制剂生产服务。Codis 在密苏里州圣路易斯、印第安纳州西摩和英国哈弗希尔拥有超过 40 万平方英尺的 cGMP 设施，将数十年的监管专业知识、开发和制造实力集于一个品牌之下。

Learn more at .

了解更多，请访问。

www.codis.com

。

Media Contacts

媒体联系人

Gillian Lott

吉莉安·洛特

Miles Fisher-Pollard

迈尔斯·费舍尔-波拉德

Codis

Orientation Marketing